Initial Case Quality Control Form

Uterine Carcinosarcoma (UCS)

<u>Instructions:</u> This form should be completed for all cases submitted for TCGA, prior to the shipment of samples to the BCR.

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

Tissue	Source Site (TSS):	TSS ID:	TSS	Unique F	atient ID		Interv	viewer l	Name: _			Interview Date///
Tumo	Tumor Information: The following sections are to be provided by a Pathologist											
#	# Question Entry Alternatives								Working Instructions			
1	Histologic Subtype of Tumor Submitted for TCGA	☐ Uterine Car	rcinosarco	oma/ Ma	lignant M	Indicate the confirmed diagnosis of the tumor submitted for TCGA. 3081934						
2	Tumor Type	☐ Primary (p.	☐ Primary (primary untreated malignant biospecimen)								Indicate the type of tumor submitted for TCGA. 328124 This is a biospecimen that has not been treated with chemotherapy or radiation prior to resection.	
3	Anatomic Site of Frozen Biospecimen	☐ Uterus	□ Uterus								Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA. 2735776	
4	Anatomic Organ Sub- Division of Frozen Biospecimen	☐ Myometriu	☐ Endometrium ☐ Fundus uteri ☐ Myometrium ☐ Unknown - Uterus, NOS ☐ Lower uterine segment/ Isthmus uteri							Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA. 2008006		
Date	of Cancer Sample Procure	ement		-								
5	Month of Cancer Sample Procurement	□ 01 □ 02	1 03 1	□ 04 □	05 🗖 0	5 □ 07	□ 08	1 09	1 0	1 1	1 2	Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008197
6	Day of Cancer Sample	□ 01 □ 02 □ 13 □ 14 □ 25 □ 26	□ 15 □	1 16 □	05 □ 0 17 □ 1 29 □ 3	3 🗖 19	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the malignant tissue submitted for TCGA. $\underline{3008195}$
7	Year of Cancer Sample Procurement				_							Provide the year of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008199
8	Method of Cancer Sample Procurement	☐ Surgical Re ☐ Endometri ☐ Endometri ☐ Full Hyster ☐ Partial Hys ☐ Hysterecto ☐ Other Meth	al Biopsy al curetta rectomy terectom my, NOS	y)							Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. 3103514
9	Other Method of Cancer Sample Procurement				_							If the procedure performed to obtain the malignant tissue is not included in the provided list, specify the procedure. $\underline{2006730}$
10	Country Where Cancer Sample was Procured				_							Provide the country where the tissue submitted for TCGA was procured. 3203072

#	Question	Entry Alternatives	Working Instructions
11	Race	 □ American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. □ Asian	Provide the patient's race using the defined categories. 2192199
12	Ethnicity	 Not Hispanic or Latino A person not meeting the definition of Hispanic or Latino. Hispanic or Latino A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated Not provided or available. Unknown	Provide the patient's ethnicity using the defined categories. 2192217
13	Vessel Used	☐ Cryovial ☐ Cassette ☐ Other, specify ☐ Biospecimen Storage Bag ☐ Cryomold	Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA. 3081940
14	Other Vessel Used		If the vessel used to ship the tissue to the BCR is not included in the provided list, specify the vessel used. 3288137
15	Is tumor sample being submitted for macrodissection?	□ Yes □ No	Indicate whether the tumor sample submitted to the BCR is intended to undergo Laser Cryo-Enrichment (LCE) after the BCR receives the sample. 3288488
16	Was sample prescreened at site?	□ Yes □ No	Indicate whether the sample submitted to the BCR was prescreened at the TSS. 3081942
Tum	or Slides Submitted		
<u>17</u>	Types of Slides Submitted	□ Physical Top Slide □ Digital Top Slide Image □ Physical FFPE Slide □ Digital FFPE Slide Image	Indicate the type(s) of slide(s) submitted to the BCR. 3521909 Top Slide Definition: Slide cut directly from frozen biospecimen = mirror image of inked surface
<u>18</u>	Slide/Digital Image ID #		Provide the slide ID for each slide (physical and digital image) submitted to the BCR. 2321277

V4.07 090612

#	Question	Entry Alternatives	Working Instructions
Tumo	or Information If the TSS is	submitting multiple pieces of the same primary tumor for this case; complete the followir	g information for each piece of tumor sent to the BCR.
<u>19</u>	Tumor Identifier		Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID. 3288096
<u>20</u>	Weight of Frozen Tumor	(mg) (0.2cm³ (0.6cm * 0.6cm * 0.6cm) = ~200mg	Provide the weight of the tumor sample submitted for TCGA. 3081946 Weight can be estimated based on the size of the tumor submitted.
<u>21</u>	Tumor Nuclei %	(%)	Provide the percent of tumor nuclei for the sample submitted for TCGA. 2841225 Check with the BCR to confirm the current acceptable TCGA metrics.
22	Necrosis %	(%)	Provide the percent of necrosis for the sample submitted for TCGA. 2841237 Check with the BCR to confirm the current acceptable TCGA metrics.
Norm	al Information A normal co	ntrol must be present to qualify.	
20	Type(s) of Normal Control Check all that apply	☐ Whole Blood ☐ Extracted DNA from Blood ☐ Buffy Coat ☐ Non-Neoplastic Control Tissue*	Indicate the type of normal control submitted for this case. 3081936 *Non-neoplastic Control Tissue may only be submitted with NCI approval.
Norn	nal Control: Whole Blood, B	uffy Coat, or Lymphocytes	Species.
21	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147
22	Month of Normal Sample Procurement	01 02 03 04 05 06 07 08 09 10 11 12	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
23	Day of Normal Sample Procurement	01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196
24	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
<u>25</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
Norn	nal Control: Extracted DNA	from Blood	
26	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147
27	Month of Normal Sample Procurement	□ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
28	Day of Normal Sample Procurement	01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196

V4.07 090612

#	Question	Entry Alternatives	Working Instructions
29	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
30	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
<u>31</u>	Extracted DNA Quantity	(μg)	Provide the quantity (µg) of the normal control sample sent to the BCR for TCGA. 3288185
32	Extracted DNA Quantification Method		Provide the quantification method of the normal control sample sent to the BCR for TCGA. 3288186
33	Extracted DNA Concentration	(μg/μL)	Provide the concentration ($\mu g/\mu L$) of the normal control sample sent to the BCR for TCGA. 3288187
34	Extracted DNA Volume	(μL)	Provide the volume (μ L) of the normal control sample sent to the BCR for TCGA. 3288188
Norn	nal Control: Non-Neoplastic	Control Tissue	
35	Method of Normal Sample Procurement	☐ Surgical Resection ☐ Other Method (please specify)	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147
36	Other Method of Normal Sample Procurement		If the procedure performed to obtain the normal sample is not included in the provided list, specify the procedure. 3288151
37	Month of Normal Sample Procurement	□ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12	Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
38	Day of Normal Sample	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196
39	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197
<u>40</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
41	Anatomic Site of Non- Neoplastic Control Tissue	☐ Uterine Cervix – NOS ☐ Omentum ☐ Fallopian tube ☐ Myometrium ☐ Ovary ☐ Other (please specify)	If the normal control type is normal tissue, indicate the anatomic site of the non-neoplastic control tissue submitted for TCGA. 3081938 Site matched is preferred.
42	Other Site of Non- Neoplastic Control Tissue		If the normal control type is normal tissue and the anatomic site is not included in the provided list, specify the site of the non-neoplastic control. 3288189
43	Proximity of Normal Tissue to Tumor	☐ Distal (> 2cm) from the primary tumor	If the normal control type is normal tissue, confirm that the submitted normal tissue was at least 2cm away from the primary tumor.

Page 5	Initial Case Quality Control Form	V4.07 090612
	Uterine Carcinosarcoma (UCS)	

Pug	e J	Initial Case Quality Control Form	V4.07 090012					
		Uterine Carcinosarcoma (UCS)						
#	Question	Entry Alternatives	Working Instructions					
			3088708 Adjacent (≤ 2cm) Normal Tissue is not accepted for this tissue type. Unknown Normal Tissue is not acceptable for this tissue type. If the normal control type is normal tissue, provide the slide ID					
<u>44</u>	Normal Slide ID#		for the physical top slide OR the digital slide image of the normal control being sent to the BCR. 3288217					
	ication: By providing the below to the below to the below to the below to the below	ow information, the Principal Investigator acknowledges that the information provided b	y the institution is true and correct and has been					
Pathology Review Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.								
45	Name of Pathologist		Provide the name of the Pathologist that provided the information for all previous sections. 3288225					
46	Date of Pathologist Review		Provide the date of the pathology review performed by the TSS pathologist above. 3288224					
Prin	cipal Investigator/Authoriz	zed Designee Confirmation						
47	Percent Tumor Nuclei meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics for TCGA. 3288520 Check with the BCR to confirm the current acceptable TCGA metrics.					
48	Percent Necrosis meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA. 3288524 Check with the BCR to confirm the current acceptable TCGA metrics.					
49	De-Identified Pathology Report Submitted?	□ Yes □ No	Confirm that a de-identified pathology report will be sent to BCR prior to or with the shipment of the physical samples. 3288292					
			Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the					

diagnosis found on the patient's pathology report for the tumor being sent to the BCR. Is the histologic diagnosis 3288300 on the CQCF (as If "yes," skip related question below. determined by the TSS The diagnosis is considered to be consistent if at least one of the following criteria are met: pathology review of the ☐ Yes ■ No 1) Diagnosis on the CQCF is identical to the pathology **50** TCGA frozen section top report for the tumor being sent to the BCR. slide) consistent with the 2) Diagnosis on the CQCF includes as least one of the histology listed in the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable for TCGA. final diagnosis on the 3) Diagnosis on the CQCF is "histology, NOS" (i.e., pathology report? Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histologic group Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable

#	Question	Entry Alternatives	Working Instructions							
			subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements.							
57	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	 □ Macrodissection performed at TSS to select for a region containing an acceptable TCGA diagnosis (see note at right) □ Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right) □ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) 	If the diagnosis provided on this form is not consistent with the diagnosis found on the pathology report provided, specify a reason for this inconsistency. 328315 If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the original pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form". In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance.							
58	History of Other Malignancy	 □ None □ History of Prior Malignancy □ History of Synchronous/ Bilateral Malignancy □ Both History of Synchronous/ Bilateral and Prior Malignancy 	Indicate whether the patient has a history of malignancies. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA. 3382736 If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.							
59	History of Neoadjuvant Treatment <i>for Tumor</i> <i>Submitted for TCGA</i>	□ None □ Radiation prior to sample procurement* □ Pharmaceutical treatment prior to sample procurement* □ Both pharmaceutical treatment and radiation prior to sample procurement*	Indicate whether the patient received therapy for this cancer prior to the sample procurement of the tumor submitted for TCGA . If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instruction. 3382737 *Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the procurement of the sample submitted for TCGA are exclusionary.							
60	Consent Status	☐ Consented ☐ Exemption 4* ☐ Deceased ☐ Waiver*	Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. 3288361 *Exemptions and waivers for consent must be approved by NCI.							
Date	Date of Consent									
61	Month of Consent	01 02 03 04 05 06 07 08 09 10 11 01	If the patient was formally consented, provide the month of consent. 3081955							
62	Day of Consent	01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	If the patient was formally consented, provide the day of consent. 3081957							

Pag	e 7	Initial Case Quality Control Form Uterine Carcinosarcoma (UCS)	V4.07 090612
#	Question	Entry Alternatives	Working Instructions
			If the patient was formally consented, provide the year of

63	Year of Consent													If the patient was formally consented, provide the year of consent. 3081959
Dat	te of Death Do not complete	date of c	leath, if բ	oatient f	ormally	consen	ted.							
64	Month of Death	1 01	1 02	1 03	1 04	1 05	1 06	1 07	□ 08	1 09	1 0	1 1	1 2	If the patient consented by death, provide the month of death. 2897026
65	Day of Death	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	If the patient consented by death, provide the day of death. 2897028
66	Year of Death													If the patient consented by death, provide the year of death. $\frac{2897030}{}$
Principal Investigator or Designee Signature									Prir	nt Name	!			//

 $I\ acknowledge\ that\ the\ above\ information\ provided\ by\ my\ institution\ is\ true\ and\ correct\ and\ has\ been\ quality\ controlled.$